The need to redefine preeclampsia

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 4, 2012, Pages 347-357

  Espinoza, Jimmy ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenic imbalance; Gestational hypertension; Preeclampsia; Proteinuria; SFlt 1; Uteroplacental ischemia; VEGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOGENIC FACTOR; BENZETHONIUM CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1; NITRITE; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; VERY LOW DENSITY LIPOPROTEIN;

ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE MEASUREMENT; CREATININE URINE LEVEL; DISEASE SEVERITY; FETUS GROWTH; GESTATIONAL AGE; GLYCEMIC CONTROL; HELLP SYNDROME; HUMAN; LEUKOCYTE; MATERNAL HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PLACENTA DISORDER; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY TOXEMIA; PREGNANT WOMAN; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SMALL FOR DATE INFANT; SPHYGMOMANOMETER; TONIC CLONIC SEIZURE; TROPHOBLAST; TWIN TWIN TRANSFUSION SYNDROME; UTERINE ARTERY;

EID: 84863216280     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.691093     Document Type: Review

References (136)

1. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67-75
2. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010;115:365-75
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-S22
4. Kuo VS, Koumantakis G, Gallery ED. Proteinuria and its assessment in normal and hypertensive pregnancy. Am J Obstet Gynecol 1992;167:723-8
5. Higby K, Suiter CR, Phelps JY, et al. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 1994;171:984-9
6. Goldkrand JW, Jackson MJ. Blood pressure measurement in pregnant women in the left lateral recumbent position. Am J Obstet Gynecol 1997;176:642-3
7. Netea RT, Bijlstra PJ, Lenders JW, et al. Influence of the arm position on intra-arterial blood pressure measurement. J Hum Hypertens 1998;12:157-60
8. Eser I, Khorshid L, Gunes UY, Demir Y. The effect of different body positions on blood pressure. J Clin Nurs 2007;16:137-40
9. Verrij EA, Nieuwenhuizen L, Bos WJ. Raising the arm before cuff inflation increases the loudness of Korotkoff sounds. Blood Press Monit 2009;14:268-73
10. Van Dongen PW, Eskes TK, Martin CB, Van't Hof MA. Postural blood pressure differences in pregnancy. A prospective study of blood pressure differences between supine and left lateral position as measured by ultrasound. Am J Obstet Gynecol 1980;138:1-5
11. Hovinga G, Aarnoudse JG, Huisjes HJ. The effect of supine and lateral positions on intra-arterial pressure in hypertensive pregnancies. Am J Obstet Gynecol 1978;131:233-8
12. Mariotti G, Alli C, Avanzini F, et al. Arm position as a source of error in blood pressure measurement. Clin Cardiol 1987;10:591-3
13. Reinders LW, Mos CN, Thornton C, et al. Time poor: rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertens Pregnancy 2006;25:81-91
14. Shennan A, Gupta M, Halligan A, et al. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996;347:139-42
15. Duggan PM. Which Korotkoff sound should be used for the diastolic blood pressure in pregnancy? Aust NZ J Obstet Gynaecol 1998;38:194-7
16. Lopez MC, Belizan JM, Villar J, Bergel E. The measurement of diastolic blood pressure during pregnancy: which Korotkoff phase should be used? Am J Obstet Gynecol 1994;170:574-8
17. Brown MA, Buddle ML, Farrell T, et al. Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. Lancet 1998;352:777-81
18. Johenning AR, Barron WM. Indirect blood pressure measurement in pregnancy: korotkoff phase 4 versus phase 5. Am J Obstet Gynecol 1992;167:577-80
19. Franx A, Evers IM, van der Pant KA, et al. The fourth sound of Korotkoff in pregnancy: a myth. Eur J Obstet Gynecol Reprod Biol 1998;76:53-9
20. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV
21. Caetano M, Ornstein MP, von Dadelszen P, et al. A survey of canadian practitioners regarding diagnosis and evaluation of the hypertensive disorders of pregnancy. Hypertens Pregnancy 2004;23:197-209
22. Pomini F, Scavo M, Ferrazzani S, et al. There is poor agreement between manual auscultatory and automated oscillometric methods for the measurement of blood pressure in normotensive pregnant women. J Matern Fetal Med 2001;10:398-403
23. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005;105:402-10
24. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. Lancet 2002;359:1877-90
25. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998;105:300-3
26. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004;190:1520-6
27. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005
28. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58
29. Karumanchi SA, Epstein FH. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int 2007;71:959-61
30. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83
31. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005;48:372-86
32. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003;111:600-2
33. Barleon B, Reusch P, Totzke F, et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001;4:143-54
34. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540-8
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
36. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
37. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
38. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9
39. Espinoza J, Uckele JE, Starr RA, et al. Angiogenic imbalances: the obstetric perspective. Am J Obstet Gynecol 2010;203:17-18
40. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4
41. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44
42. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8
43. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-75
44. Austgulen R, Isaksen CV, Chedwick L, et al. Pre-eclampsia: associated with increased syncytial apoptosis when the infant is small-for-gestational-age. J Reprod Immunol 2004;61:39-50
45. Crocker IP, Cooper S, Ong SC, Baker PN. Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol 2003;162:637-43
46. Leung DN, Smith SC, To KF, et al. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001;184:1249-50
47. Sargent IL, Germain SJ, Sacks GP, et al. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003;59:153-60
48. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in human pregnancy-its relevance for pre-eclampsia. Placenta 1999;20:531-9
49. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998;105:632-40
50. Chua S, Wilkins T, Sargent I, Redman C. Trophoblast deportation in pre-eclamptic pregnancy. Br J Obstet Gynaecol 1991;98:973-9
51. Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007;71:977-84
52. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50:1142-7
53. Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145:4838-45
54. Nevo O, Soleymanlou N, Wu Y, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-93
55. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40
56. Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2011
57. Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012;59:256-64
58. Bolin M, Wiberg-Itzel E, Wikstrom AK, et al. Angiopoietin-1/angiopoietin- 2 ratio for prediction of preeclampsia. Am J Hypertens 2009;22:891-5
59. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-38
60. Poon LC, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23-33
61. Thilaganathan B, Wormald B, Zanardini C, et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010;115:1233-8
62. Thilaganathan B, Ralph E, Papageorghiou AT, et al. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci 2009;16:788-93
63. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326-13
64. Harrington K, Cooper D, Lees C, et al. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996;7:182-8
65. Albaiges G, Missfelder-Lobos H, Lees C, et al. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000;96:559-64
66. Papageorghiou AT, Yu CK, Cicero S, et al. Second-trimester uterine artery doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002;12:78-88
67. Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol2001;18:441-9
68. Napolitano R, Santo S, D'Souza R, et al. Sensitivity of higher, lower and mean second-trimester uterine artery Doppler resistance indices in screening for pre-eclampsia. Ultrasound Obstet Gynecol 2010;36:573-6
69. Aquilina J, Thompson O, Thilaganathan B, Harrington K. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery doppler. Ultrasound Obstet Gynecol 2001;17:477-84
70. Cetin I, Huppertz B, Burton G, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32(Suppl):S4-16
71. Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011;25:343-54
72. Belfort M, Van Veen T, White GL, et al. Low maternal middle cerebral artery doppler resistance indices can predict future development of preeclampsia. Ultrasound Obstet Gynecol 2011
73. Tuuli MG, Odibo AO. First- and second-trimester screening for preeclampsia and intrauterine growth restriction. Clin Lab Med 2010;30:727-46
74. Pedrosa AC, Matias A. Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers. J Perinat Med 2011;39:619-35
75. Anderson UD, Olsson MG, Kristensen KH, et al. Review: biochemical markers to predict preeclampsia. Placenta 2012;33(Suppl):S42-7
76. Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012
77. Espinoza J. Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opin Med Diagn 2012;6:109-20
78. Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539-44
79. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-23
80. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63
81. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-51
82. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004;23:101-11
83. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3-18
84. Aggarwal PK, Jain V, Sakhuja V, et al. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006;69:621-4
85. Crispi F, Dominguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195:201-7
86. Signore C, Mills JL, Qian C, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108:338-44
87. Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;125:911-9
88. Kusanovic JP, Romero R, Espinoza J, et al. Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008;198:382-8
89. Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 2007;20:495-507
90. Boutsikou T, Malamitsi-Puchner A, Economou E, et al. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006;82:235-9
91. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007;112:51-7
92. Odegard RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol 2000;96:950-5
93. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001;97:533-8
94. Moldenhauer JS, Stanek J, Warshak C, et al. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189:1173-7
95. Sebire NJ, Goldin RD, Regan L. Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 2005;25:117-18
96. Rasmussen S, Irgens LM. Fetal growth and body proportion in preeclampsia. Obstet Gynecol 2003;101:575-83
97. Aardema MW, Saro MC, Lander M, et al. Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: two different pathophysiological entities? Clin Sci (Lond) 2004;106:377-82
98. Espinoza J, Romero R, Mee KY, et al. Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 2006;34:447-58
99. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006;27:939-58
100. Kuzmina IY, Hubina-Vakulik GI, Burton GJ. Placental morphometry and doppler flow velocimetry in cases of chronic human fetal hypoxia. Eur J Obstet Gynecol Reprod Biol 2005;120:139-45
101. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery doppler indices. Hum Reprod 2004;19:206-9
102. Olofsson P, Laurini RN, Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993;49:161-8
103. Voigt HJ, Becker V. Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 1992;20:139-47
104. Lin S, Shimizu I, Suehara N, et al. Uterine artery doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995;85:760-5
105. Aardema MW, Oosterhof H, Timmer A, et al. Uterine artery doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses. Placenta 2001;22:405-11
106. Madazli R, Somunkiran A, Calay Z, et al. Histomorphology of the placenta and the placental bed of growth restricted foetuses and correlation with the Doppler velocimetries of the uterine and umbilical arteries. Placenta 2003;24:510-16
107. Sagol S, Ozkinay E, Oztekin K, Ozdemir N. The comparison of uterine artery doppler velocimetry with the histopathology of the placental bed. Aust NZ J Obstet Gynaecol 1999;39:324-9
108. Kim YM, Chaiworapongsa T, Gomez R, et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002;187:1137-42
109. Kim YM, Bujold E, Chaiworapongsa T, et al. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003;189:1063-9
110. Avagliano L, Bulfamante GP, Morabito A, Marconi AM. Abnormal spiral artery remodelling in the decidual segment during pregnancy: from histology to clinical correlation. J Clin Pathol 2011;64:1064-8
111. Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011
112. Benirschke K, Kaufmann P, Baergen R. Molar Pregnancies In: Pathology of the human placenta, Eds. Benirschke K and Kaufmann P and Baergen P, New York:Springer;2006
113. Sandrim VC, Palei AC, Cavalli RC, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 2009;15:115-20
114. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vascular growth and function in the human placenta. Reproduction 2009;138:895-902
115. Espinoza J, Espinoza AF. Pre-eclampsia: a maternal manifestation of a fetal adaptive response? Ultrasound Obstet Gynecol 2011;38:367-70
116. Espinoza J, Espinoza AF, Power GG. High fetal plasma adenosine concentration: a role for the fetus in preeclampsia? Am J Obstet Gynecol 2011;205:485.e24-7
117. Odegard RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol 2000;96:950-5
118. Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000;183:148-55
119. Xiong X, Fraser WD. Impact of pregnancy-induced hypertension on birthweight by gestational age. Paediatr Perinat Epidemiol 2004;18:186-91
120. Espinoza J, Kusanovic JP, Bahado-Singh R, et al. Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension? J Ultrasound Med 2010;29:1103-15
121. Ostlund I, Haglund B, Hanson U. Gestational diabetes and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004;113:12-16
122. Yogev Y, Xenakis EM, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol 2004;191:1655-60
123. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187-207
124. Stepan H, Schaarschmidt W, Jank A, et al. Use of angiogenic factors (sFlt-1/ PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol 2010;214:234-8
125. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation2012;125:911-9
126. Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205:469-8
127. Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010;202:40-7
128. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58
129. Knudsen UB, Kronborg CS, von Dadelszen P, et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens Int J Womens Cardiovasc Health 2012;2:8-15
130. Masuyama H, Suwaki N, Nakatsukasa H, et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006;194:551-6
131. Ohkuchi A, Hirashima C, Matsubara S, et al. Serum sFlt1: plGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 2009;28:95-108
132. Holston AM, Qian C, Yu KF, et al. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol 2009;200:392-10
133. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481-7
134. McCarthy FP, Kingdom JC, Kenny LC, Walsh SK. Animal models of preeclampsia; uses and limitations. Placenta 2011;32:413-19
135. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-50
136. Lee W, Balasubramaniam M, Deter RL, Yeo L, Hassan SS, Gotsch F, Kusanovic JP, Goncalves LF, Romero R. New fetal weight estimation models using fractional limb volume. Ultrasound Obster Gynecol. 2009;34:556-65